How did ME&MGopen and its biomarkers meet the main challenges of applying digital tools to the understanding of generalized myasthenia gravis?

Overcoming Challenges in Digital Biomarker Collection for Myasthenia Gravis: Insights from the ME&MGopen Study

In June 2025 in Helsinki, Finland, we presented the ME&MGopen study at the EAN annual congress, which demonstrates the feasibility of using the ME&MGopen™ app to assess the symptoms of patients with generalized myasthenia gravis (gMG).

The data, obtained in real life, reflect the quality of the biomarkers, while highlighting the limitations associated with performing the tests.